Efficacy of immune checkpoint inhibitors in renal cell carcinoma venous tumour thrombus shrinkage (UroCCR 128)

1

Kidney cancer is the seventh leading cause of cancer globally, with 450,000 new cases and 179,000 deaths reported in 2020.
2

Immune checkpoint inhibitors (ICIs) have improved overall survival and response rates in metastatic renal cell carcinoma compared to sunitinib.
3

Venous tumor thrombus (VTT) complicates surgical management in renal cell carcinoma, often requiring complex procedures and resulting in higher morbidity.
4

A retrospective study evaluated the efficacy of ICI-based therapy in 44 patients with locally advanced or metastatic RCC and VTT.
5

The study found that 82% of patients received first-line ICI therapy, with a median VTT diameter of 22 mm at baseline.

World Journal Of Urology

by Fabien Moinard-Butot, Jonathan Thouvenin, Pierre Bigot, Nieves Martinez-Chanza, Victor Gaillard, Roberto Luigi Cazzato, Romain Boissier, Gaëlle Margue, Philippe Boudier, Denis Maillet, Marine Gross-Goupil, Jean-Christophe Bernhard, Philippe Barthélémy
January 10, 2025

1